EUVIMEDEUVIMED entdecken
Crossref

177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy

Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, William Counter, Bao Ho, Andrew O Yam, Peter Wilson, Remy Niman, Maria Ayers, Aron Poole, Adam Hickey, Shikha Agrawal und 7 weitere

Journal of Nuclear Medicine · 2023-03 · 64 (3) · 410-415

DOI: 10.2967/jnumed.122.264677 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.09.2022. Verfasst von Nikeith John und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 72-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu-PSMA is an effective treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and adjust treatment may be improved using predictive tools. This study aimed to evaluate change in 177Lu-PSMA SPECT quantitative parameters to monitor treatment response.

Methods

One hundred twenty-seven men with progressive mCRPC previously treated with androgen-signaling inhibition (99%) and chemotherapy (71%) received a median of 3 (interquartile range [IQR], 2-5) 8-GBq (IQR, 8-8.5 GBq) doses of 177Lu-PSMA-I&T. Imaging included 68Ga-PSMA-11 PET/CT (SUVmax > 15 at a single site and > 10 at all sites > 2 cm), diagnostic CT, and 177Lu SPECT/CT from vertex to mid thigh (24 h after treatment). 177Lu SPECT/CT quantitative analysis was undertaken at cycles 1 (baseline) and 2 (week 6) of treatment. Clinical and biochemical results were assessed to evaluate prostate-specific antigen (PSA) progression-free survival (PFS) and overall survival (OS).

Results

A PSA reduction of more than 50% was seen in 58% (74/127). The median PSA PFS was 6.1 mo (95% CI, 5.5-6.7), and OS was 16.8 mo (95% CI, 13.5-20.1). At the time of analysis, 41% (52/127) were deceased. At baseline and week 6, 76% (96/127) had analyzable serial 177Lu SPECT/CT imaging. SPECT total tumor volume (TTV) was reduced between baseline and week 6 in 74% (71/96; median, -193; IQR, -486 to -41). Any increase in SPECT TTV between baseline and week 6 was associated with significantly shorter PSA PFS (hazard ratio, 2.5; 95% CI, 1.5-4.2; P = 0.0008) but not OS. Median PSA PFS in those with an increase in SPECT TTV was 3.7 mo (95% CI, 2.8-6.8), compared with 6.7 mo (95% CI, 5.8-10.6) in those with no increase in SPECT TTV. An increase in SPECT TTV greater than 20% was also associated with PSA PFS (hazard ratio, 1.9; 95% CI, 1.2-3.0; P = 0.008) but less significantly than any change in SPECT TTV. There was a significant difference in PSA PFS between patients with both increased PSA and SPECT TTV and patients with reduced SPECT TTV and PSA (median, 2.8 vs. 9.0 mo; P < 0.0001).

Conclusion

Increasing PSMA SPECT TTV on quantitative 177Lu SPECT/CT predicts short progression-free survival and may play a future role as an imaging response biomarker, identifying when to cease or intensify 177Lu-PSMA therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantMaleHumansProgression-Free SurvivalPositron Emission Tomography Computed TomographySingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

SPECTlutetium-PSMAmetastatic prostate cancerresponse biomarker

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
  • Garvan Institute of Medical Research, Sydney, New South Wales, Australia.
  • Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia.
  • MIM Software, Inc., Cleveland, Ohio; and.
  • NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.

Zitieren

APA

John, N., Pathmanandavel, S., Crumbaker, M., Counter, W., Ho, B., Yam, A. O., Wilson, P., Niman, R., Ayers, M., Poole, A., Hickey, A., Agrawal, S., Perkins, G., Kallinen, A., Eslick, E., Stockler, M. R., Joshua, A. M., Nguyen, A., & Emmett, L. (2023). 177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine, 64(3), 410-415. https://doi.org/10.2967/jnumed.122.264677

Vancouver

John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. 177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy. Journal of Nuclear Medicine. 2023;64(3):410-415. doi:10.2967/jnumed.122.264677

BibTeX
@article{John2023,
  author = {John, Nikeith and Pathmanandavel, Sarennya and Crumbaker, Megan and Counter, William and Ho, Bao and Yam, Andrew O and Wilson, Peter and Niman, Remy and Ayers, Maria and Poole, Aron and Hickey, Adam and Agrawal, Shikha and Perkins, Gary and Kallinen, Annukka and Eslick, Enid and Stockler, Martin R and Joshua, Anthony M and Nguyen, Andrew and Emmett, Louise},
  title = {177 Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177 Lu-PSMA-I&T Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {3},
  pages = {410--415},
  doi = {10.2967/jnumed.122.264677}
}
Kostenlos starten →